RT Journal Article
SR Electronic
T1 SARS-CoV-2 Community Transmission During Shelter-in-Place in San Francisco
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.15.20132233
DO 10.1101/2020.06.15.20132233
A1 Chamie, Gabriel
A1 Marquez, Carina
A1 Crawford, Emily
A1 Peng, James
A1 Petersen, Maya
A1 Schwab, Daniel
A1 Schwab, Joshua
A1 Martinez, Jackie
A1 Jones, Diane
A1 Black, Douglas
A1 Gandhi, Monica
A1 Kerkhoff, Andrew D.
A1 Jain, Vivek
A1 Sergi, Francesco
A1 Jacobo, Jon
A1 Rojas, Susana
A1 Tulier-Laiwa, Valerie
A1 Gallardo-Brown, Tracy
A1 Appa, Ayesha
A1 Chiu, Charles
A1 Rodgers, Mary
A1 Hackett, John
A1 ,
A1 Kistler, Amy
A1 Hao, Samantha
A1 Kamm, Jack
A1 Dynerman, David
A1 Batson, Joshua
A1 Greenhouse, Bryan
A1 DeRisi, Joe
A1 Havlir, Diane V.
YR 2020
UL http://medrxiv.org/content/early/2020/06/17/2020.06.15.20132233.abstract
AB Background We characterized SARS-CoV-2 infections in a densely-populated, majority Latinx San Francisco community six-weeks into the city’s shelter-in-place order.Methods We offered SARS-CoV-2 reverse transcription-PCR and antibody (Abbott ARCHITECT IgG) testing, regardless of symptoms, to all residents (>4 years) and workers in a San Francisco census tract (population: 5,174) at outdoor, community-mobilized events over four days. We estimated SARS-CoV-2 point prevalence (PCR-positive) and cumulative incidence (antibody or PCR-positive) in the census tract and evaluated risk factors for recent (PCR-positive/antibody-negative) versus prior infection (antibody-positive/PCR-negative). SARS-CoV-2 genome recovery and phylogenetics were used to measure viral strain diversity, establish viral lineages present, and estimate number of introductions.Results We tested 3,953 persons: 40% Latinx; 41% White; 9% Asian/Pacific Islander; and 2% Black. Overall, 2.1% (83/3,871) tested PCR-positive: 95% were Latinx and 52% asymptomatic when tested. 1.7% of residents and 6.0% of workers (non-census tract residents) were PCR-positive. Among 2,598 census tract residents, estimated point prevalence of PCR-positives was 2.3% (95%CI: 1.2-3.8%): 3.9% (95%CI: 2.0-6.4%) among Latinx vs. 0.2% (95%CI: 0.0-0.4%) among non-Latinx persons. Estimated cumulative incidence among residents was 6.1% (95%CI: 4.0-8.6%). Prior infections were 67% Latinx, 16% White, and 17% other ethnicities. Among recent infections, 96% were Latinx. Risk factors for recent infection were Latinx ethnicity, inability to shelter-in-place and maintain income, frontline service work, unemployment, and household income <$50,000/year. Five SARS-CoV-2 phylogenetic lineages were detected.Conclusion SARS-CoV-2 infections from diverse lineages continued circulating among low-income, Latinx persons unable to work from home and maintain income during San Francisco’s shelter-in-place ordinance.Competing Interest StatementMary Rodgers and John Hackett Jr. work for Abbott Laboratories. ARCHITECT SARS-CoV-2 test kits were provided by Abbott Laboratories. Charles Chiu is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC) and receives research support funding from Abbott Laboratories.Funding StatementThe study was supported by the Chan Zuckerberg Biohub, UCSF, and a Program for Breakthrough Biomedical Research award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of California, San Francisco (UCSF) Committee on Human Research determined that the study met criteria for public health surveillance.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings will be available following publication.